1. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD
- Author
-
Wei Shen, Linwen Zhu, Shibo Wu, Hang Chen, Yinyu Mu, Ni Li, Kaitai Liu, Saiqi Ni, Menglu Sang, and Guodong Xu
- Subjects
Aging ,Lung Neoplasms ,T-Lymphocytes ,medicine.medical_treatment ,T cell ,Adenocarcinoma of Lung ,Gefitinib ,Biomarkers, Tumor ,medicine ,Humans ,CTLA-4 Antigen ,long noncoding RNA ,prognostic signature ,Lung cancer ,Hepatitis A Virus Cellular Receptor 2 ,B-Lymphocytes ,tumor immune microenvironment ,business.industry ,Macrophages ,Cancer ,infiltration of immune cell ,Cell Biology ,Immunotherapy ,Cell cycle ,Prognosis ,lung adenocarcinoma ,Actin cytoskeleton ,medicine.disease ,Gene Expression Regulation, Neoplastic ,medicine.anatomical_structure ,Cancer research ,Adenocarcinoma ,RNA, Long Noncoding ,business ,Research Paper ,medicine.drug - Abstract
The tumor immune microenvironment of lung cancer is associated with prognosis and immunotherapy efficacy. Long noncoding RNAs are identified as prognostic biomarkers associated with immune functions. We constructed a signature comprising differentially expressed immune-related lncRNAs to predict the prognosis of patients with lung adenocarcinoma. We established the immune-related lncRNA signature by pairing immune-related lncRNAs regardless of expression level and lung adenocarcinoma patients were divided into high- and low-risk groups. The prognosis of patients in the two groups was significantly different; The immune-related lncRNA signature could serve as an independent lung adenocarcinoma prognostic indicator. The signature correlated negatively with B cell, CD4+ T cell, M2 macrophage, neutrophil, and monocyte immune infiltration. Patients with low risk scores had a higher abundance of immune cells and stromal cells around the tumor. Gene set enrichment analysis showed that samples from low-risk group were more active in the IgA production in intestinal immune network and the T and B cell receptor signaling pathway. High-risk groups had significant involvement of the cell cycle, DNA replication, adherens junction, actin cytoskeleton regulation, pathways in cancer, and TGF-β signaling pathways. High risk scores correlated significantly negatively with high CTLA-4 and HAVCR2 expression and higher median inhibitory concentration of common anti-tumor chemotherapeutics (e.g., cisplatin, paclitaxel, gemcitabine) and targeted therapy (e.g., erlotinib and gefitinib). We identified a reliable immune-related lncRNA lung adenocarcinoma prognosis model, and the immune-related lncRNA signature showed promising clinical prediction value.
- Published
- 2021